CClinicalTrials.gg
Not yet recruitingNCT07588529NSAILUpdated May 14, 2026

Is Nipple Stimulation Effective for Inducing Labor and Acceptable to Patients, Nurses, and Providers?

An interventional study of Electric breast pump for nipple stimulation and induction of labor in Pregnancy and Induction of Labor, sponsored by University of Kansas Medical Center. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

In this study the investigators will be testing the use of the Symphony PLUS® breast pump for nipple stimulation. Typically, breast pumps are used to start breast milk production and collect breast milk in patients after delivering their baby. The device uses cup-shaped pieces called flanges that are placed over the patient's nipples and then a gentle vacuum or suction is applied. The mechanical effect of the suction on the nipple is thought to cause the release of a substance called oxytocin in one's body, which encourages labor and contractions to begin. Some reasons why nipple stimulation might be better than other induction of labor methods are that it allows the patient to have more control over their induction process, it uses the patient's own oxytocin instead of synthetic (or factory-produced) oxytocin, and it may shorten the time that it takes to deliver the baby.

Read the detailed description

Patients will be randomly assigned (like rolling the dice) to one of 2 groups.

  • Group 1 will follow the standard induction of labor protocol at KUMC. In other words, their induction process will not look any different than if they were not a participant in this study. Their induction process may include, but is not limited to, medications and/or devices to make the body more ready to deliver the baby, medications to increase the uterus muscle contractions, medications to decrease the pain associated with labor, etc. Group 1 will not use nipple stimulation at all as part of their labor.
  • Group 2 will follow the standard induction of labor protocol with the addition of nipple stimulation using the Symphony PLUS® breast pump for a 2-hour time period. At the time in their labor when the medical team would normally deem them appropriate to initiate synthetic oxytocin (Pitocin), nipple stimulation will be started instead. The breast pump will be placed over one nipple at a time and put on its default vacuum settings. Every 15 minutes, the patient will switch to stimulating the alternate nipple with no breaks of time in between. Depending on how fast the contractions are, the research team may increase or decrease the strength of the breast pump. This will continue for 2 hours, after which they will stop doing nipple stimulation. They will then resume normal induction of labor care as deemed appropriate by the nurses and doctors.

Patients will have a 1 in 2 chance (50%) of being randomized to either Group 1 or Group 2. Group assignments will be chosen by a randomization tool. Patients and the study team will be aware of which treatment they are under.

After delivering the baby, both groups will take a survey about their induction experience while they are in the hospital. After the survey is collected, patients have completed participation in this study. Patients will continue to receive standard care with their primary physician team.

The investigators will take information about the patients and their medical care from the electronic medical record for research purposes. The investigators will be analyzing things such as how long it took from the beginning of induction to the delivery of the baby, if there were any unexpected events, how much synthetic oxytocin was used, and other information about the induction and the health of the baby. The investigators will also analyze the results of the surveys completed.

02

Conditions studied

  • Pregnancy
  • Induction of Labor

Keywords

  • nipple stimulation
  • breast stimulation
  • induction
  • labor
  • induction of labor
03

In context

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 483 studies on the registry; 113 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

All patients presenting to KUMC labor \& delivery for IOL will be considered for this study.

Maternal

  • ≥18 years old and ≤ 50 years old
  • ≥37wga and ≤ 42wga
  • Intact amniotic membranes
  • English speaking Fetal
  • Cephalic presentation

Exclusion criteria

Exclusion Criteria:

Maternal

  • Inability to give informed consent
  • History of cesarean delivery or uterine myomectomy
  • History of uterine rupture
  • Intrahepatic cholestasis of pregnancy
  • Maternal life-threatening conditions
  • Active HSV
  • Gestational hypertension, Preeclampsia (severe or w/o severe features), HELLP, chronic hypertension on medications

Placental

  • Placenta previa, vasa previa
  • Suspicion for abnormally adherent placenta
  • Chorioamnionitis
  • Placental abruption

Fetal

  • Multifetal gestation
  • category 2 or 3 fetal heart tracing upon presentation (does not include isolated variable deceleration)
  • EFW > 5000 grams in mother with diabetes
  • EFW > 4500 grams in mother without diabetes
  • Fetal demise
  • Fetal growth restriction \<10th centile
  • Any other contraindication for vaginal birth or anticipation of need for NICU for care of baby
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Control

    Patients randomized to the control group will follow standard induction of labor protocol, which may include, but is not limited to, misoprostol, Foley catheter, and synthetic oxytocin (Pitocin). In other words, their induction will be the same as if they were not enrolled in the study.

    Other: induction of labor

  • Experimental
    Nipple Stimulation

    Patients randomized to the experimental group will undergo standard IOL protocol with the addition of nipple stimulation. At the time when the labor and delivery team deems a patient suitable for Pitocin initiation, patients will begin using a Symphony PLUS® breast pump for nipple stimulation. The breast pump will be turned on and placed on one breast (around the nipple) for 15 minutes, alternating breasts every 15 minutes. The default pump vacuum settings will be utilized. Contraction pattern and pump settings will be assessed every 30 minutes and adjusted if needed to maintain uterine contractions at a rate between 3 and 5 contractions per 10 minutes averaged over 30 minutes. Patients will perform nipple stimulation for no greater and no less than 2 hours. They will then resume normal care.

    Other: Electric breast pump for nipple stimulation

Interventions

  • OtherElectric breast pump for nipple stimulation

    Symphony PLUS® breast pump. What distinguishes this induction of labor nipple stimulation study is how we will be applying the nipple stimulation. Many other studies exist, but they apply the stimulation in an uneven or inconsistent manner. They often do not specify how they interpret active and latent labor. Our study will be using nipple stimulation only for 2 hours per experimental participant so that we can better quantify the effect that nipple stimulation has on the labor process.

  • Otherinduction of labor

    Patients randomized to the control group will follow standard induction of labor protocol, which may include, but is not limited to, misoprostol, Foley catheter, and synthetic oxytocin (Pitocin).

06

What researchers measure

Primary outcomes

  1. Total Duration of Labor

    The investigators will measure the time between induction of labor initiation and delivery of the baby.

    Time frame: From beginning of induction of labor to delivery of the baby (for each patient).

Secondary outcomes

  1. Average amount of Pitocin used

    Average Pitocin per patient used in the different study arms (nulliparous control, nulliparous experimental, multiparous control, multiparous experimental).

    Time frame: From beginning of induction of labor to delivery of the baby (for each patient).

  2. Average maximum concentration of Pitocin

    The investigators will measure the average maximum concentration of Pitocin needed for each study arm (nulliparous control, nulliparous experimental, multiparous control, multiparous experimental).

    Time frame: From beginning of induction of labor to delivery of the baby (for each patient).

  3. Delivery method

    Delivery method (C-section, spontaneous vaginal, or operative vaginal) by percentage needed for each study arm (nulliparous control, nulliparous experimental, multiparous control, multiparous experimental).

    Time frame: Time taken for delivery of newborn

  4. Maternal adverse events

    Adverse events (uterine tachysystole, postpartum hemorrhage, any other adverse event) by percentage that occur in each study arm (nulliparous control, nulliparous experimental, multiparous control, multiparous experimental).

    Time frame: From beginning of induction of labor to patient being discharged in postpartum period.

  5. NICU admission

    Percentage of newborns requiring NICU admission per study arm (nulliparous control, nulliparous experimental, multiparous control, multiparous experimental).

    Time frame: From delivery of newborn to discharge from hospital.

  6. APGAR score

    Average APGAR score of newborns in each study arm (nulliparous control, nulliparous experimental, multiparous control, multiparous experimental).

    Time frame: In the minutes directly after delivery

  7. Acceptability of nipple stimulation as an induction of labor method

    Surveys will be administered to patients in their postpartum period, labor and delivery nurses after the patient portion of the study has been completed, and OBGYN providers Pre and Post patient portion of the study. These surveys will ask about familiarity with nipple stimulation, how they liked using it, and if they would use it again for induction of labor.

    Time frame: From before patient participation to after all patients (48 total) have participated.

07

Study locations

1 site
  • University of Kansas Medical Center
    Kansas City, Kansas 66103, United States
08

References and documents

Publications

  • Chayen B, Tejani N, Verma U. Induction of labor with an electric breast pump. J Reprod Med. 1986 Feb;31(2):116-8. PubMed 3959016 ↗
  • Stark EL, Athens ZG, Son M. Intrapartum nipple stimulation therapy for labor induction: a randomized controlled external pilot study of acceptability and feasibility. Am J Obstet Gynecol MFM. 2022 Mar;4(2):100575. doi: 10.1016/j.ajogmf.2022.100575. Epub 2022 Jan 15. PubMed 35042047 ↗
  • Adewole IF, Franklin O, Matiluko AA. Cervical ripening and induction of labour by breast stimulation. Afr J Med Med Sci. 1993 Dec;22(4):81-5. PubMed 7839936 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07588529
Lead sponsor
University of Kansas Medical Center
Responsible party
Rachel DiTeresi (Associate Professor, Obstetrics and Gynecology, University of Kansas Medical Center) — Principal investigator
First posted
May 14, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 14, 2026

Study contacts

Bethany Snyder
Contact
bsnyder3@kumc.edu
9135233650
Rachel DiTeresi, MD
Contact
rditeresi@kumc.edu
913-588-6200
Brian Brost, MD
study chair · Vice Chair of Education and Innovation in the Department of Obstetrics and Gynecology at the University of Kansas School of Medicine
Rachel DiTeresi, MD
principal investigator · Clerkship Director for Obstetrics and Gynecology Department at KUMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion